Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine

NCT00310674 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00310674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00310674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2004
Completion date
Not reported
Enrollment
150
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of meningococcal infection